Technologies → DNA-Seq → Circulating Tumor DNA

High-sensitivity cfDNA and ctDNA analysis services

Cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) extraction and analysis services for drug development, from discovery to large clinical trials.

Book a meeting

Ask a question

cfDNA and ctDNA analysis in liquid biopsies

Circulating tumor DNA (ctDNA) testing is challenging due to its very low quantities in liquid biopsies and the presence of short, fragmented DNA. This requires an optimized extraction protocol and highly sensitive and robust methodologies, such as next-generation sequencing (NGS), for accurate detection and quantification.

We perform qPCR and dPCR on short cfDNA and ctDNA targets

ctDNA and cfDNA testing services at TATAA

NGS-based ctDNA and cfDNA analysis enables the detection of tumor-derived DNA fragments in the bloodstream, providing non-invasive insights.

Monitor residual cancer cells post-treatment by analyzing ctDNA and cfDNA to detect relapse.
Track ctDNA and cfDNA levels to assess the effectiveness of ongoing therapies.
Detect genetic changes in tumors during treatment by analyzing ctDNA and cfDNA for adaptive therapies.
Identify resistance mutations emerging during therapy using ctDNA and cfDNA for timely interventions.
Assess tumor mutations non-invasively with cfDNA and ctDNA liquid biopsies, eliminating the need for tissue biopsies.
Track ctDNA and cfDNA dynamics to monitor patient responses and disease progression in clinical trials.

Detect and quantify cell free DNA and circulating DNA fragments shed by tumors.

	Whole genome sequencing	Whole exome sequencing	Targeted Gene Panels	Circulating Tumor DNA (ctDNA)
Library preparation	IDT xGen DNA Library Prep Kit EZ with UDIs	IDT xGen DNA Library Prep Kit EZ with UDIs, combined with xGen Exome Hyb Panel v2
Recommended sample input	Fresh frozen cells or tissue EDTA whole blood or PAXgene DNA tubes High quality FFPE (IDT DNA Integrity score > 1.0)	Fresh frozen cells or tissue EDTA whole blood or PAXgene DNA tubes High quality FFPE (IDT DNA Integrity score > 1.0)
Recommended DNA input	Range: 0.1 ng – 1 ug Standard input: 100ng	Range: 0.1 ng – 1 ug Standard input: 100ng	Range: 0.1 ng – 1 ug Standard input: 100ng	Range: 0.1 ng – 1 ug Standard input: 100ng
Recommended sequencing	Paired-end sequencing	Paired-end sequencing	Paired-end sequencing	Paired-end sequencing
Deliverables	Quality-controlled data Fastq files Study report	Quality-controlled data Fastq files Study report	Quality-controlled data Fastq files Study report	Quality-controlled data Fastq files Study report

DNA-seq services

GLP and GCLP compliant laboratory

We are accredited for Good Laboratory Practice (GLP) by the Swedish Board for Accreditation and Conformity Assessment (SWEDAC) for qPCR, dPCR, and molecular biology. In addition, we are Good Clinical Laboratory Practice (GCLP) compliant to ensure the safe and reliable analysis of clinical samples.

Difference between cfDNA and ctDNA

Cell-free DNA (cfDNA) is fragmented DNA that freely circulates in blood and other biofluids. It can originate from various sources, including fetal DNA in prenatal screenings, donor DNA in transplant rejection monitoring, and immune cell DNA in inflammatory diseases. Circulating tumor DNA (ctDNA) is a subset of cfDNA derived explicitly from tumor cells through apoptosis, necrosis, or active secretion.

Both cfDNA and ctDNA serve as valuable biomarkers in precision medicine, oncology, and disease monitoring. Non-invasive, liquid biopsies assess disease status, treatment response, and progression.